What is Ibrutinib?

Yihui Pharmaceuticals invests wholeheartedly in introducing its first rate item - Ibrutinib API, a progressive build that stands at the front of current drug headways. Ibrutinib, a small molecule inhibitor, has collected huge consideration for its strong helpful applications in the therapy of different malignancies, essentially focusing on B-cell diseases.

Basic Information

Product Name: Ibrutinib

CAS: 936563-96-1

MF:C25H24N6O2

MW:440.5

EINECS:805-642-2

MDL No.:MFCD20261150

Purity: 99%

Package: 100g;1kg;5kg,10kg,25kg

Used:  Pharma grade & Lab research

Stability: Stable

Structural formula:  

Specifications and Parameters

Chemical Composition

Role and Function 

Ibrutinib API assumes an imperative part in the treatment of B-cell malignancies by targeting and inhibiting  Bruton's tyrosine kinase (BTK). BTK is a key compound drawn in with B-cell flagging pathways, which are essential for the development and endurance of compromising B-cells. By irreversibly impeding BTK, Ibrutinib actually disturbs these pathways, prompting the suppression of tumor growth and the enlistment of apoptosis in cancercells.

The efficacy of Ibrutinib has been shown in different B-cell malignancies, including CLL, MCL, and WM. It enjoys shown enormous clinical benefits, for instance, further progression-free survival, overall survival, and quality of life for patients. Its targeted approach additionally limits off-target effects, making it well-tolerated by patients.

Beyond its role as a targeted therapy, Ibrutinib API has contributed to significant advancements in our understanding of B-cell biology and signaling pathways. It has been extensively studied in preclinical and clinical settings, leading to insights into resistance mechanisms and potential combination therapies.

Overall, Ibrutinib's ability to selectively inhibit BTK and its remarkable efficacy in treating B-cell malignancies have revolutionized oncology, providing new treatment options and hope for patients with these diseases.

Synthesis Process 

The synthesis of Ibrutinib includes a fastidious process guaranteeing high purity and quality. Beginning from painstakingly chosen unrefined substances, the combination incorporates key advances like condensation, cyclization, and purification. Our best medical infrastructure andrigorous protocols ensure a steady and dependable manufacturing process, satisfying international guidelines.

Quality Standards

Yihui Pharmaceuticals places paramount importance on quality. Our CAS 936563-96-1 conforms to the highest industry standards, adhering to ISO, Kosher, Halal, and GMP certifications. Stringent quality control measures are implemented at every stage of production, assuring purity, potency, and safety. These certifications underscore our commitment to delivering a product that meets the diverse needs of global pharmaceutical markets.

Application Fields in Various Industries 

The versatility of CAS 936563-96-1 extends beyond oncology,in the biotechnology industry, the product plays a crucial role in the development of targeted therapies for various diseases. Its viability in adjusting B-cell capability has prompted its fuse into antibody-drug conjugates , which specifically convey cytotoxic agents to malignant cells while limiting harm to healthy tissue.

The product also finds application in clinical trials, serving as a benchmark in evaluating the efficacy and safety of novel therapies. Its robust clinical data and established safety profile make it an ideal comparator in clinical studies across multiple indications.

Moreover, the product's potential in treating autoimmune disorders has piqued the interest of the pharmaceutical industry. Companies are investigating the improvement of novel formulations that target B-cell-interceded incendiary illnesses like multiple sclerosis, rheumatoid joint inflammation, and lupus.

Furthermore, the product's success in oncology has led to its consideration in combination therapies with other drugs. These combinations have shown promising outcomes in further developing results in patients with relapsed or refractory B-cell malignancies.

Yihui - Your Trusted Partner

Yihui is a distinguished manufacturer and supplier of Ibrutinib API, ensuring product quality and compliance with international standards. Our dedication to excellence is reflected in the certifications we hold, affirming our commitment to delivering premium pharmaceutical solutions. For inquiries and purchases, contact us at sales@yihuipharm.com.

In conclusion, Yihui Pharmaceuticals takes pride in presenting the product, a testament to our commitment to excellence, quality, and innovation in the pharmaceutical industry. Join us in the journey towards advancing healthcare globally.